BIOGEN MA INC.;THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
发明人:
Richard S. Blumberg,Timo Rath,Kristi Baker,Adam Mezo,Zachary Taylor,Kevin Mcdonnell,Rosa Maria Silva Garcia Grenha
申请号：
US16293879
公开号：
US20200023034A1
申请日:
2019.03.06
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.
